<DOC>
<DOCNO>EP-0658557</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Eburnane derivatives, processes for their preparation and pharmaceutical compositions containing them
</INVENTION-TITLE>
<CLASSIFICATIONS>A61P2500	C07D47122	A61P2500	A61P2524	A61K31435	A61P4300	A61P2526	C07D46100	A61P4300	C07D47100	C07D47106	A61P2520	C07D46100	A61P2528	A61K31435	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61P	C07D	A61P	A61P	A61K	A61P	A61P	C07D	A61P	C07D	C07D	A61P	C07D	A61P	A61K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61P25	C07D471	A61P25	A61P25	A61K31	A61P43	A61P25	C07D461	A61P43	C07D471	C07D471	A61P25	C07D461	A61P25	A61K31	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of general formula (I): 
<
IMAGE
>
  in which A represents a divalent radical chosen from 
<
IMAGE
>
 and R1, R2, R3, R4, R5, R6, R7, R8, R9 and Z are as defined in the description. Medicaments.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of the general formula (I):
wherein:


R
1
, R
2
, R
3
 and R
4
, which may be identical or different, are:

selected independently of one another from:

a hydrogen atom,
a halogen atom,
a hydroxy radical,
a linear or branched (C
1
-C
6
)-alkyl radical optionally substituted by one or
more halogen atoms, by one or more amino groups, by one or more nitro

groups, by one or more linear or branched (C
1
-C
6
)-alkoxy groups or by one
or more aryl radicals, selected from phenyl and naphthyl, which are

themselves optionally substituted by one or more halogen atoms, nitro or
amino groups or (C
1
-C
6
)-alkyl or (C
1
-C
6
)-alkoxy radicals,
and a linear or branched (C
1
-C
6
)-alkoxy group optionally substituted by one
or more halogen atoms, by one or more amino groups, by one or more nitro

groups, or by one or more linear or branched (C
1
-C
6
)-alkoxy groups,
or R
1
, R
2
, R
3
 and R
4
, taken in pairs and carried by adjacent carbon atoms, form a
methylenedioxy or ethylenedioxy group,
R
6
 and R
7
:

either each simultaneously represent hydrogen, adopting a 
cis
-configuration
with respect to one another,
or together form a bond,
R
8
 and R
9
either each simultaneously represent hydrogen, adopting a 
cis
- or

trans
-configuration with respect to one another,
or together form a bond in the case where R
6
 and R
7
 also together
form a double bond,

represents a bivalent radical selected from

Z is selected from oxygen and sulphur,
R
5
 is selected from hydrogen and a linear or branched (C
1
-C
6
)-alkyl group optionally
substituted by one or more:


halogen atoms,
linear or branched (C
1
-C
6
)-alkoxy radicals,
phenyl radicals optionally substituted by one or more halogen atoms, linear or
branched (C
1
-C
6
)-alkyl radicals, or linear or branched (C
1
-C
6
)-alkoxy radicals,
those alkyl and alkoxy radicals optionally being substituted by one or more aryl

radicals, selected from phenyl and naphthyl, which are unsubstituted or
substituted by one or more groups selected from the halogens and amino, nitro,

(C
1
-C
6
)-alkyl and (C
1
-C
6
)-alkoxy radicals,
or radicals


wherein R
10
 and R
11
 are selected independently of one
another from hydrogen, linear or branched (C
1
-C
6
)-alkyl radicals and linear or
branched (C
1
-C
6
)-alkoxy radicals,
 
their possible N-oxides, enantiomers and diastereoisomers and also, where

appropriate, their pharmaceutically acceptable acid addition salts.
Compound according to claim 1 that is 10-methoxy-2,7,14,15-tetrahydro-14-aza-20,21-dinoreburnamenin-15-one,

its N-oxides, enantiomers and diastereoisomers and pharmaceutically acceptable acid
addition salts.
Compound according to claim 1 that is 10-chloro-2,7,14,15-tetrahydro-14-aza-20,21-dinoreburnamenin-15-one,

its N-oxides, enantiomers and diastereoisomers and pharmaceutically acceptable acid
addition salts.
Compound according to claim 1 that is 14,15-dihydro-14-aza-20,21-dinoreburnamenine,

its N-oxides, enantiomers and diastereoisomers and pharmaceutically acceptable acid
addition salts.
Compound according to claim 1 that is 10,11-methylenedioxy-2,7,14,15-tetrahydro-14-aza-20,21-dinoreburnamenin-15-one,

its N-oxides, enantiomers and diastereoisomers and pharmaceutically acceptable acid
addition salts.
Compound according to claim 1 that is 9-methoxy-1a,2,3,6,7,7a,12a,12b-octahydro-1
H
,5
H
-benzo[5,6]pyrrolizino[2,1,7-ija]
quinolizin-1-one,

its N-oxides, enantiomers and diastereoisomers and pharmaceutically acceptable acid
addition salts.
Process for the preparation of the compounds of formula (I), characterised in that
the compound of formula (II):


wherein R
1
, R
2
, R
3
 and R
4
 are as defined for formula (I),

is subjected to the action of a compound of formula (III):

wherein R' represents an alkyl group containing from 1 to 6 carbon atoms in a
straight or branched chain, and Hal represents a halogen atom,

to yield a compound of formula (IV):

wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

which is then hydrogenated to form a mixture of 
cis
-enantiomers of formula (Va):

wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

by the action of a hydrogenation agent in an acid medium and in an anhydrous solvent,

it optionally being possible for an epimerisation reaction to be effected, at a low
temperature, in an anhydrous solvent using an alkali metal hydride in order to obtain a

mixture of 
trans
-enantiomers of formula (Vb): 

wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

the totality of the compounds of formulae (Va) and (Vb) forming the totality of the
compounds of formula (V):


wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

which compounds of formula (V) are again subjected to hydrogenation, in a trifluoroacetic
acid medium, by means of sodium cyanoborohydride, to yield a compound of

formula (VI):

wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

which is subjected:

either: A/ to the action of an alkali metal hydride in an anhydrous solvent, under
reflux, to yield a compound of formula (Xa): 


wherein R
1
, R
2
, R
3
 and R
4
 are as defined above,

or: B/ to the action of sodium nitrite, in an acid medium, then in the presence
of zinc, to yield a hydrazine of formula (VII):


wherein R
1
, R
2
, R
3
, R
4
 and R' are as defined above,

which is then cyclised under the action of an alkali metal hydride to
form a compound of formula (VIII):


wherein R
1
, R
2
, R
3
 and R
4
 are as defined above,

and then subjected, if desired, to the action of a compound of
formula (IX):


R'
5
-Hal
, 

wherein R'
5
 has the same meanings as the radical R
5
 as defined for
formula (I), with the exception of hydrogen, and Hal represents a

halogen atom,

after the action of a deprotonating agent, to yield a compound of
formula (Xb):


wherein R
1
, R
2
, R
3
, R
4
 and R'
5
 are as defined above,

it being possible, if desired, for the ketone function of the totality of the compounds of
formulae (VIII), (Xa) and (Xb) to be reduced to form the corresponding hydrocarbon, or

subjected to the action of Lawesson's reagent, in order to be converted into the
corresponding thioketone, the totality of the compounds of formulae (VIII), (Xa) and

(Xb), as well as their possible reduction products or their possible thio analogues,
forming the totality of the compounds 
of formula (I/1):

wherein R
1
, R
2
, R
3
 and R
4
 are as defined above and A is as defined for
formula (I),

which are:

either: subjected to the action of a gentle oxidising agent to yield a compound
of formula (I/2): 


wherein R
1
, R
2
, R
3
, R
4
 and A are as defined above,
or: subjected to the action of a strong oxidising agent to yield a compound
of formula (I/3):


wherein R
1
, R
2
, R
3
, R
4
 and A are as defined above,

the totality of the compounds of formulae (I/1), (I/2) and (I/3) forming the totality of the
compounds of formula (I) which are, where appropriate, purified by a conventional

purification technique, separated into their possible enantiomers and diastereoisomers
and converted into their N-oxides or pharmaceutically acceptable acid addition salts.
Pharmaceutical compositions that contain as active ingredient at least one
compound according to any one of claims 1 to 6, one of its possible N-oxides,

enantiomers, diastereoisomers or pharmaceutically acceptable acid addition salts,
alone or in combination with one or more suitable inert, non-toxic excipients or carriers.
Pharmaceutical compositions according to claim 8 that contain at least one active
ingredient, namely an inducer of tyrosine hydroxylase, according to any one of claims

1 to 6 and that can be used in the treatment of depression, anxiety, memory disorders
in the course of senescence and/or degenerative diseases and in the treatment of

Parkinson's disease.
</CLAIMS>
</TEXT>
</DOC>
